Modulation of p53 expression using antisense oligonucleotides complementary to the 5′-terminal region of p53 mRNA in vitro and in the living cells

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Gorska, Agnieszka ^a   Swiatkowska, Agata ^a   Dutkiewicz, Mariola ^a   Ciesiolka, Jerzy ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISOPROTEIN; MESSENGER RNA; PROTEIN P53; RIBONUCLEASE H;

ANIMAL CELL; ARTICLE; CELL STRAIN MCF 7; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR MECHANICS; NONHUMAN; NUCLEIC ACID HYBRIDIZATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RABBIT; REGULATORY MECHANISM; RETICULOCYTE LYSATE; RNA STRUCTURE; RNA TRANSLATION; START CODON; TERMINAL OLIGOPYRIMIDINE TRACT;

5' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL-FREE SYSTEM; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RABBITS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84892924023     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078863     Document Type: Article

References (47)

1. Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, et al. (2011) Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 18: 1815-1824.
2. Muller PA, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15: 2-8.
3. Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9: 749-758.
4. Vousden KH, Prives C (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413-431.
5. Powell DJ, Hrstka R, Candeias M, Bourougaa K, Vojtesek B, et al. (2008) Stress-dependent changes in the properties of p53 complexes by the alternative translation product p53/47. Cell Cycle 7: 950-959.
6. Wang Z, Li B (2010) Mdm2 links genotoxic stress and metabolism to p53. Protein Cell 1: 1063-1072.
7. Khoury MP, Bourdon JC (2010) The isoforms of the p53 protein. Cold Spring Harb Perspect Biol 2: a000927.
8. Khoury MP, Bourdon JC (2011) p53 Isoforms: An Intracellular Microprocessor? Genes Cancer 2: 453-465.
9. Marcel V, Hainaut P (2009) p53 isoforms - a conspiracy to kidnap p53 tumor suppressor activity? Cell Mol Life Sci 66: 391-406.
10. Olivares-Illana V, Fåhraeus R (2010) p53 isoforms gain functions. Oncogene 29: 5113-5119.
11. Bourdon JC (2005) p53 isoforms can regulate p53 transcriptional activity. Genes & Development 19: 2122-2137.
12. Candeias MM, Powell DJ, Roubalova E, Apcher S, Bourougaa K, et al. (2006) Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. Oncogene 25: 6936-6947.
13. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, et al. (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21: 6722-6728.
14. Grover R, Candeias MM, Fahraeus R, Das S (2009) p53 and little brother p53/47: linking IRES activities with protein functions. Oncogene 28: 2766-2772.
15. Yang DQ, Halaby MJ, Zhang Y (2006) The identification of an internal ribosomal entry site in the 5′-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 25: 4613-4619.
16. Blaszczyk L, Ciesiolka J (2011) Secondary structure and the role in translation initiation of the 5′-terminal region of p53 mRNA. Biochemistry 50: 7080-7092.
17. Grover R, Sharathchandra A, Ponnuswamy A, Khan D, Das S (2011) Effect of mutations on the p53 IRES RNA structure: implications for de-regulation of the synthesis of p53 isoforms. RNA Biol 8: 132-142.
18. Lu C, El-Deiry WS (2009) Targeting p53 for enhanced radio- and chemosensitivity. Apoptosis 14: 597-606.
19. Zhan Q (2005) Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutat Res 569: 133-143.
20. Mirzayans R, Andrais B, Scott A, Murray D (2012) New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol 2012: 170325.
21. Sak A, Wurm R, Elo B, Grehl S, Pottgen C, et al. (2003) Increased radiation-induced apoptosis and altered cell cycle progression of human lung cancer cell lines by antisense oligodeoxynucleotides targeting p53 and p21(WAF1/CIP1). Cancer Gene Ther 10: 926-934.
22. Liu XF, Xia YF, Li MZ, Wang HM, He YX, et al. (2006) The effect of p21 antisense oligodeoxynucleotides on the radiosensitivity of nasopharyngeal carcinoma cells with normal p53 function. Cell Biol Int 30: 283-287.
23. Tian H, Wittmack EK, Jorgensen TJ (2000) p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 60: 679-684.
24. Aartsma-Rus A, van Ommen GJ (2007) Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13: 1609-1624.
25. Mitrpant C, Adams AM, Meloni PL, Muntoni F, Fletcher S, et al. (2009) Rational design of antisense oligomers to induce dystrophin exon skipping. Mol Ther 17: 1418-1426.
26. Alvarez-Salas LM (2008) Nucleic acids as therapeutic agents. Curr Top Med Chem 8: 1379-1404.
27. Mescalchin A, Restle T (2011) Oligomeric nucleic acids as antivirals. Molecules 16: 1271-1296.
28. Liao F, Wang L, Yang LB, Zhang L, Peng X, et al. (2013) Antisense oligodeoxynucleotide inhibition as an alternative and convenient method for gene function analysis in pollen tubes. PLoS One 8: e59112.
29. Rayburn ER, Zhang R (2008) Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today 13: 513-521.
30. Wrzesinski J, Legiewicz M, Ciesiolka J (2000) Mapping of accessible sites for oligonucleotide hybridization on hepatitis delta virus ribozymes. Nucleic Acids Res 28: 1785-1793.
31. Vasa SM, Guex N, Wilkinson KA, Weeks KM, Giddings MC (2008) ShapeFinder: a software system for high-throughput quantitative analysis of nucleic acid reactivity information resolved by capillary electrophoresis. RNA 14: 1979-1990.
32. Swiatkowska A, Dutkiewicz M, Ciesiolka J (2007) Structural features of target RNA molecules greatly modulate the cleavage efficiency of trans-acting delta ribozymes. Biochemistry 46: 5523-5533.
33. Ciesiolka J, Michalowski D, Wrzesinski J, Krajewski J, Krzyzosiak WJ (1998) Patterns of cleavages induced by lead ions in defined RNA secondary structure motifs. J Mol Biol 275: 211-220.
34. +2-induced cleavage of RNA. In Hartmann RK, Bindereif A, Schön A, Westhof E, eds Handbook of RNA Biochemistry WILEY-VCH Verlag, ISBN: 978-3-527-32764-5.
35. Reuter JS, Mathews DH (2010) RNAstructure: software for RNA secondary structure prediction and analysis. BMC Bioinformatics 11: 129.
36. Cazenave C, Frank P, Busen W (1993) Characterization of ribonuclease H activities present in two cell-free protein synthesizing systems, the wheat germ extract and the rabbit reticulocyte lysate. Biochimie 75: 113-122.
37. Haeuptle MT, Frank R, Dobberstein B (1986) Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length. Nucleic Acids Res 14: 1427-1448.
38. Ravichandran LV, Dean NM, Marcusson EG (2004) Use of antisense oligonucleotides in functional genomics and target validation. Oligonucleotides 14: 49-64.
39. Dias N, Stein CA (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1: 347-355.
40. Nowotny M, Gaidamakov SA, Ghirlando R, Cerritelli SM, Crouch RJ, et al. (2007) Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol Cell 28: 264-276.
41. Chen J, Kastan MB (2010) 5′-3′-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. Genes Dev 24: 2146-2156.
42. Lykke-Andersen S, Brodersen DE, Jensen TH (2009) Origins and activities of the eukaryotic exosome. J Cell Sci 122: 1487-1494.
43. Meyer S, Temme C, Wahle E (2004) Messenger RNA turnover in eukaryotes: pathways and enzymes. Crit Rev Biochem Mol Biol 39: 197-216.
44. Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, et al. (2010) A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 5: e10682.
45. Evers MM, Pepers BA, van Deutekom JC, Mulders SA, den Dunnen JT, et al. (2011) Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One 6: e24308.
46. Candeias MM, Malbert-Colas L, Powell DJ, Daskalogianni C, Maslon MM, et al. (2008) P53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol 10: 1098-1105.
47. Kurreck J, Wyszko E, Gillen C, Erdmann VA (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 30: 1911-1918.